Replimune Group Inc (NASDAQ:REPL) surged 60% in premarket trading after the U.S. Food and Drug Administration (FDA) accepted the company’s resubmission of its Biologics License Application (BLA) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results